UK markets closed
NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.65 -0.15 (-0.19%) GOLD FUTURES
2,432.10 -6.40 (-0.26%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,815.16 +2,599.79 (+4.98%)
Halozyme Therapeutics, Inc. (HALO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 44.71 |
| Open | 44.85 |
| Bid | 44.97 x 200 |
| Ask | 45.11 x 100 |
| Day's range | 44.30 - 45.07 |
| 52-week range | 31.86 - 46.16 |
| Volume | |
| Avg. volume | 1,030,853 |
| Market cap | 5.724B |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | 18.66 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Halozyme to Participate in Upcoming Investor Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences:
- PR Newswire
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March 31, 2024, and provided an update on its recent corporate activities and outlook.
- PR Newswire
Mahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
© 2024 Yahoo. All rights reserved.